Exner T, Rickard K A, Kronenberg H
Pathology. 1980 Oct;12(4):559-66. doi: 10.3109/00313028009086808.
Prothrombin ratio (PR) ranges of 1.5-2.5 based on clinical effect are used for oral anticoagulant control with most commercially available thromboplastins, whereas with Australasian Reference Thromboplastin (ART) 2.0-3.5 is recommended. Plasmas from patients taking oral anticoagulants were concurrently tested with various thromboplastins and interrelationships between these products were determined. Although PR's with ART appear higher, in fact therapy based on ART guidelines is considerably more conservative than that monitored with most commercial thromboplastins.
基于临床效果，凝血酶原比值（PR）范围为1.5至2.5用于使用大多数市售凝血活酶进行口服抗凝控制，而对于澳大利亚参考凝血活酶（ART），建议的范围是2.0至3.5。对服用口服抗凝剂患者的血浆同时使用各种凝血活酶进行检测，并确定这些产品之间的相互关系。尽管使用ART时的PR值看起来更高，但实际上基于ART指南的治疗比使用大多数市售凝血活酶监测的治疗更为保守。
